摘要
目的 前瞻性评估坎地沙坦治疗原发性高血压的降压疗效和安全性。方法 130例轻中度原发性高血压患者随机服用坎地沙坦4～8mg或福辛普利10～20mg共20周，服药前后行动态血压监测（ABPM），观察24h收缩压（SBP）和舒张压（DBP）、谷峰比值、下一次给药前6h血压变化、降压有效率和不良反应。结果 坎地沙坦和福辛普利均能有效降低血压，20周治疗有效率分别为74％和73％（P〉0．05），坎地沙坦谷峰比值较福辛普利高（SBP：79％VS63％，P〈0．05；DBP：79％vs62％P〈0．05；），且较福辛普利具有更强的减低清晨2：00～8：00血压的作用（P〈0．05）。坎地沙坦不良反应发生率较少。结论 坎地沙坦治疗轻中度原发性高血压安全有效，耐受性好，可持续24h理想的控制血压。
Objective To investigate the clinical safety and efficacy of candesartan in the treatment of patient with mild to moderate hypertension. Methods One hundred thirty patients with mild to moderate hypertension were randomly divided into candesartan （ n = 66, 4- 8mg/d ） or fosinopril（ n - 64, 10- 20mg/d ） for 20 weeks, Ambulatory blood pressure monitoring was undertaken before and after the treatment. 24 hours mean blood pressure , trough/peak ratio, BP in 2：00- 8：00AM, effective rate, and side effect were evaluated. Results Both SBP and DBP decreased in two groups after the treatment. The effective rates were 74 % in eandesartan group and 73 % in fosinopril group. The trough/peak ratio in candesartan group was higher than in fosinopril group （SBP79% vs 63%, DBP 79% vs 62% ）. Reduction of mean SBP and DBP in candesartan group was greater than that in fosinopril group during 2：00-8：00AM. Candesartan was well tolerated. Conclusion Candesartan is safe and effective in treatment of mild to moderate hypertension.
出处
《中国心血管杂志》
2006年第3期177-179,共3页
Chinese Journal of Cardiovascular Medicine
